May 2 |
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
|
May 2 |
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
|
May 2 |
BridgeBio spinout launches with $200M for KRAS cancer drugs
|
May 1 |
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
|
Apr 25 |
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
|
Apr 7 |
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|